Germany’s medical cannabis market is dominated by cheap, high-THC flowers bought by patients who overwhelmingly pay privately. That was not the plan in 2017 when the "Cannabis als Medizin" law let doctors prescribe flowers and extracts as a last-resort therapy for patients looking for alternatives to the mainstream therapies. The German market’s shape is the result of regulatory design, not of medical need: reclassification, telemedicine, self-payment and an import supply biased towards high THC turned a re-writing of the rules into something that behaves much like a consumer market.
What the market looks like
The main characteristic of the German market is that flowers, not extracts, oils or synthetic equivalents are the bestsellers. A 2022 survey that included privately paying patients found that 89.9% of respondents were using cannabis flowers, at an estimated average of 336 mg THC a day, far more than the users of other cannabis products.
In a 2020 survey (Szejko et al., 2024) of 1,028 patients, Bedrocan (22% THC, under 1% CBD) was the most used product, followed by Bakerstreet (19% THC, under 1% CBD) and Pedanios (22% THC, 1% CBD). Overall, seven of the eight most common strains were high-THC; only one was balanced.
Germany's medical cannabis market has developed into a large and increasingly competitive market for dried flowers, with a preference for THC concentration and price
Since the 2024 reform, the range of the offer has grown and the THC content has risen even further. In twelve months of sales from one single online pharmacy (Manthey et al., 2026), 71% of flowers sold contained at least 20% THC, while flowers with under 15% of THC accounted for less than 3% of sales. The offer for CBD-dominant flowers was small and they were the least bought.
Why it became like this
The main cause was the 2017 decision to allow flowers to be sold alongside approved medicines. Flowers were never required to prove their superiority against any standard treatment, and patients did not find any: the Szejko survey found that effectiveness was reported at about 80% regardless of the flower, and that there was no link between condition and flower choice. Without any official clinical differentiation, flowers and brands compete on what users can see, mainly THC percentage and price.
The second cause was the split between insured and self-paying patients: after cannabis was removed from the Narcotics Act in April 2024, prescriptions became ordinary e-prescriptions, which made telemedicine and mail-order delivery a practical channel. The Manthey et al. study notes that insurance-reimbursed volumes stayed largely flat while total demand grew, so the growth came almost mostly from self-payers. A self-payer has no insurer limiting product choice and every reason to compare euros per milligram of THC.
What it says about German consumers
The data from the studies describes an experienced buyer who is price-sensitive and looking for THC. Many patients in 2020 had used cannabis for more than a year, and only 30% were satisfied with value for money, which fits users who already knew illicit prices.
This makes the line between medical and recreational use hard to see. Manthey et al. argue that the rising demand for cheap, high-THC flowers is hard to reconcile with a medical-only audience for which the evidence that THC is a predictor of efficacy is thin.
A brief comparison illustrates the point. The Netherlands, historically with a single producer and five varieties supplied through a centrally regulated system, saw a more balanced sales mix (in one survey 47% used Bedrocan, while the rest used lower-THC or balanced flowers) and stable daily doses for years. Germany has no such limit on range, and no legal coffee-shop venues like in the Netherlands to cater for recreational demand, so part of that demand runs through pharmacies (de Hoop et al., 2018).
Conclusion
The Germany medical cannabis market has developed into a large and increasingly competitive market for dried flowers, with a preference for THC concentration and price. Research suggests that this development has been facilitated by regulatory changes, simplified prescribing, the growth of online pharmacies and a substantial demand from privately-paying consumers.
The resulting market differs from more tightly controlled medical cannabis systems, like the historical Dutch model, where patients had access to fewer standardized products. However, these differences do not prove that Germany's market is driven primarily by recreational consumers.
The central question for policymakers is whether the current approach can preserve appropriate medical oversight while providing patients with affordable access to cannabis. Answering it will require better data on prescriptions, patient diagnoses, purchasing behavior and treatment outcomes.
Deine Daten bleiben privat. Wir verwenden Cookies, um dein Erlebnis zu verbessern. Wir verfolgen dich nicht über andere Websites hinweg, geben deine medizinischen Informationen niemals an Werbetreibende weiter und verkaufen deine Daten nicht. Datenschutzerklärung